Athira Pharma Rebounds from Alzheimer’s Setbacks with $90 Million Breast Cancer Deal
Athira Pharma is executing a dramatic strategic shift, pivoting its primary focus from Alzheimer's disease to oncology following years marked ...
Athira Pharma is executing a dramatic strategic shift, pivoting its primary focus from Alzheimer's disease to oncology following years marked ...
© 2025 Seattle Today - Seattle’s premier source for breaking and exclusive news.
© 2025 Seattle Today - Seattle’s premier source for breaking and exclusive news.